Stay updated on BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial
Sign up to get notified when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.

Latest updates to the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page
- Check7 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the study details with an access-denied screen.SummaryDifference17%

- Check14 days agoChange DetectedRevision updated from v3.6.6 to v3.7.0, indicating a newer page version. This change appears to be a non-content update to the page's template or formatting rather than any study details.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedThe page revision tag was updated to v3.6.6, replacing the previous v3.6.5 on the study record.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page revision was updated from v3.6.4 to v3.6.5, indicating a new version of the ClinicalTrials.gov page was published. This appears to be a minor update or correction rather than a change to the study data or eligibility criteria.SummaryDifference0.1%

- Check70 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4. This indicates a minor page refresh or metadata update on the study details page without altering the study information.SummaryDifference0.1%

- Check91 days agoChange DetectedThe revision label on the page updated to v3.6.3, replacing the previous v3.6.0.SummaryDifference0.1%

Stay in the know with updates to BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.